The VEGF Consortium aims to develop a transnational collaborative network dedicated to large integrative and multidisciplinary genomic studies of the VEGF-A in order to generate applicable knowledge for medical practice thanks to the following specific objectives: -to combine data from multiple cohorts in order to identify VEGF-A '-omics' profiling in health and noncommunicable diseases -to elucidate the pivotal role of VEGF-A in the pathophysiology of non-communicable diseases -to demonstrate the patients' stratification potential of VEGF-A '-omics' profiling -to implement the research results into clinical practice and establish the role of VEGF-A as a predictive, preventive, diagnostic and prognostic biomarker -to provide information on the effect of VEGF-A '-omics' profiling in side effects and response to therapy through pharmacogenomics studies Given the wide range of the research field and the need for application of different methodologies in order to successfully achieve its objectives, the consortium is composed of scientists with different and complementary expertise and with a large range of resources such as large study populations, research materials and harmonized data.
Although the VEGF Consortium was officially founded on 2014, it was based on the long-term collaboration between some of its founding partners. Therefore, a number of significant results have been published already, and many projects are ongoing, with promising preliminary results.
Among the most basic steps was the identification through two genome-wide association studies (GWAS) of 10 genetic variants that explain >50% of the circulating VEGF-A levels variability [10, 11] . This is a unique finding among GWAS. In most GWAS, the identified variants do not explain >10% of the individual variability of the assessed traits. This finding has strengthened our belief that VEGF-A will indeed be used as strong biomarker for personalized medicine. Significant associations between some of these polymorphisms and intermediate phenotypes of chronic diseases have been identified since then: high-density and low-density lipoprotein [12] , L-selectin gene expression [13] and free tri-iodothyronin (FT3) levels [14] . Significant epistatic interactions between these variants were observed for intercellular adhesion molecule 1 (ICAM-1), E-selectin, interleukin 6 and tumor necrosis factor α (TNF-α) plasma levels [13] . Concerning specific disease risk, we have shown that these polymorphisms and/or their epistatic interactions can affect the risk for depression [15] , and for autoimmune thyroid diseases [14] , whereas no associations were found for diabetes type 2 [16] .
Concerning the expression isoforms of VEGF-A gene, we have shown that these are significantly associated with ICAM-1, L-selectin and TNF-α expression [13] and with specific autoimmune thyroid diseases [17] .
Furthermore, we have also identified associations between VEGF-A circulating levels and thyroid hormones levels [17] and with ICAM-1 and E-selectin levels [13] .
Through a candidate gene approach of polymorphisms in genes involved in angiogenesis, we have identified direct and epistatic effects of variants on nitric oxide synthase 3 (NOS3), CD14
+ monocytes, matrix metalloproteinases (MMPs) and interleukin 4 receptor (ILR4) genes with levels of VEGF-A and VEGF-A expression isoforms, but also gene × environment interactions [18] .
An important result is also the production of two patents based on the results of studies performed by partners of the consortium [19, 20] .
Several projects are ongoing and focused on CVD intermediate phenotypes, thyroid diseases, cancer and stroke.
Three face-to-face meetings have been organized to date: Paris (2014), Budapest (2015) and Santorini (2016) .
The VEGF Consortium is an ambitious international collaboration that aims to pave the way for the implementation of VEGF-A in personalized medicine and routine clinical practice. The designed projects take advantage of the wide expertise of its partners, the large infrastructures of cohorts and biobanks and a combination of the most up-to-date "-omics" approaches for generating multidimensional data, as well as 'systems medicine' approaches, network analysis and computational modeling methodologies.
Among its major originalities is that it integrates commercialization and communication platforms, targeting the valid and easy measurement of the identified biomarkers in large-scale settings but also the education of the general population, patients, scientists and health practitioners.
The VEGF Consortium is a novel consortium with an innovating structure and original goals. The ultimate goal is to ameliorate life expectancy, quality of life for individuals and financial benefits for health systems.
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